(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Significant Elements to Consider Prior to Applying for a Mastercard: 6 Vital Contemplations- Instructions to Choose the Best Web based Advertising Degree Program for Your Objectives
- These 2 moon rovers used cameras and lasers to hunt for simulated water ice — and one looks like WALL-E
- Ukrainian Army Converts E38 BMW 7-Series Into Multiple Rocket Launch Platform
- AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets
- 'We need everyone,' wounded reservist urges Knesset panel to advance haredi draft law
- The Delight of Camper Vans: Choosing the One That Meets Your Requirements
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- 6 Exceptionally Appraised Summer Travel Objections
